170 related articles for article (PubMed ID: 20470239)
1. Hypersensitivity vasculitis associated with leuprolide (Lupron).
Gnanaraj J; Saif MW
Cutan Ocul Toxicol; 2010 Sep; 29(3):224-7. PubMed ID: 20470239
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
3. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
5. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy.
Warnock JK; Bundren JC
Psychopharmacol Bull; 1997; 33(2):311-6. PubMed ID: 9230649
[TBL] [Abstract][Full Text] [Related]
6. What should I know about Lupron Depot for treating prostate cancer?
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
[No Abstract] [Full Text] [Related]
7. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I
Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
9. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
10. Hemothorax after Lupron therapy of a patient with pleural endometriosis--a case report and literature review.
Margolis MT; Thoen LD; Mercer LJ; Keith LG
Int J Fertil Menopausal Stud; 1996; 41(1):53-5. PubMed ID: 8673157
[TBL] [Abstract][Full Text] [Related]
11. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
Fujisaki A; Kondo Y; Goto K; Morita T
Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
13. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog.
Yu SS; Connolly MK; Berger TG; McCalmont TH
J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002
[No Abstract] [Full Text] [Related]
14. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
Chang JI; Bucci J
J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
[TBL] [Abstract][Full Text] [Related]
15. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer.
Cottreau CM; Ness RB; Modugno F; Allen GO; Goodman MT
Clin Cancer Res; 2003 Nov; 9(14):5142-4. PubMed ID: 14613992
[TBL] [Abstract][Full Text] [Related]
16. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
17. Leuprolide acetate-induced generalized papular eruption.
Burris K; Ding CY; Lim GF
J Drugs Dermatol; 2014 Jun; 13(6):755-7. PubMed ID: 24918569
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics, effects, side effects of the LH-RH agonist].
Miyanaga N; Akaza H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
[No Abstract] [Full Text] [Related]
20. Leuprolide acetate-induced dermatitis herpetiformis.
Grimwood RE; Guevara A
Cutis; 2005 Jan; 75(1):49-52. PubMed ID: 15732435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
